You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTasosartan
Accession NumberDB01349
TypeSmall Molecule
GroupsApproved
DescriptionTasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension
Structure
Thumb
Synonyms
ANA-756
Tasosartan
WAY-ana-756
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII48G92V856H
CAS number145733-36-4
WeightAverage: 411.4591
Monoisotopic: 411.180758329
Chemical FormulaC23H21N7O
InChI KeyInChIKey=ADXGNEYLLLSOAR-UHFFFAOYSA-N
InChI
InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29)
IUPAC Name
2,4-dimethyl-8-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-5H,6H,7H,8H-pyrido[2,3-d]pyrimidin-7-one
SMILES
CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • Pyridopyrimidine
  • Phenylmethylamine
  • Benzylamine
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationTasosartan is infrequently in the treatment of hypertension and heart failure.
PharmacodynamicsBy blocking the angiotensin II (AT1) receptor, the drug ultimately causes vasodilation, reduced secretion of vasopressin (ADH), reduced production and secretion of aldosterone, amongst other actions leading to the combined effect of a reduction of blood pressure.
Mechanism of actionTasosartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Tasosartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Tasosartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9849
Caco-2 permeable+0.5626
P-glycoprotein substrateSubstrate0.5771
P-glycoprotein inhibitor IInhibitor0.7645
P-glycoprotein inhibitor IIInhibitor0.5378
Renal organic cation transporterInhibitor0.524
CYP450 2C9 substrateNon-substrate0.7978
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.864
CYP450 2C9 inhibitorInhibitor0.6924
CYP450 2D6 inhibitorInhibitor0.5465
CYP450 2C19 inhibitorInhibitor0.8163
CYP450 3A4 inhibitorInhibitor0.5112
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8338
Ames testNon AMES toxic0.5066
CarcinogenicityNon-carcinogens0.8061
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8079 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6971
hERG inhibition (predictor II)Non-inhibitor0.5487
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0325 mg/mLALOGPS
logP3.07ALOGPS
logP4.18ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)2.79ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area100.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity130.61 m3·mol-1ChemAxon
Polarizability44.34 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC09CA05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AceclofenacThe risk or severity of adverse effects can be increased when Tasosartan is combined with Aceclofenac.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Tasosartan is combined with Adapalene.
AliskirenAliskiren may increase the hyperkalemic activities of Tasosartan.
AmilorideTasosartan may increase the hyperkalemic activities of Amiloride.
AmiodaroneThe metabolism of Tasosartan can be decreased when combined with Amiodarone.
AntipyrineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Antipyrine.
ApremilastThe risk or severity of adverse effects can be increased when Tasosartan is combined with Apremilast.
AprepitantThe serum concentration of Tasosartan can be increased when it is combined with Aprepitant.
ArdeparinArdeparin may increase the hyperkalemic activities of Tasosartan.
AtazanavirThe metabolism of Tasosartan can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Tasosartan can be decreased when combined with Atomoxetine.
AzapropazoneThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azelastine.
BalsalazideThe risk or severity of adverse effects can be increased when Tasosartan is combined with Balsalazide.
BemiparinBemiparin may increase the hyperkalemic activities of Tasosartan.
BenazeprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Benazepril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Benoxaprofen.
BexaroteneThe serum concentration of Tasosartan can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Tasosartan can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Tasosartan can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Tasosartan can be decreased when it is combined with Bosentan.
BromfenacThe risk or severity of adverse effects can be increased when Tasosartan is combined with Bromfenac.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Tasosartan.
CandoxatrilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Captopril.
CarbamazepineThe metabolism of Tasosartan can be increased when combined with Carbamazepine.
CarprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Carprofen.
CastanospermineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Tasosartan is combined with Celecoxib.
CeritinibThe serum concentration of Tasosartan can be increased when it is combined with Ceritinib.
CertoparinCertoparin may increase the hyperkalemic activities of Tasosartan.
ChloroquineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Chloroquine.
CilazaprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Cilazapril.
CiprofloxacinTasosartan may increase the arrhythmogenic activities of Ciprofloxacin.
ClarithromycinThe metabolism of Tasosartan can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Tasosartan can be decreased when combined with Clemastine.
ClonixinThe risk or severity of adverse effects can be increased when Tasosartan is combined with Clonixin.
ClotrimazoleThe metabolism of Tasosartan can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Tasosartan can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Tasosartan can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Tasosartan can be decreased when combined with Crizotinib.
CyclosporineTasosartan may increase the hyperkalemic activities of Cyclosporine.
CyclosporineThe metabolism of Tasosartan can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Tasosartan is combined with D-Limonene.
DabrafenibThe serum concentration of Tasosartan can be decreased when it is combined with Dabrafenib.
DalteparinDalteparin may increase the hyperkalemic activities of Tasosartan.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tasosartan.
DarunavirThe metabolism of Tasosartan can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Tasosartan can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Tasosartan can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Tasosartan can be decreased when combined with Delavirdine.
DexamethasoneThe serum concentration of Tasosartan can be decreased when it is combined with Dexamethasone.
DiclofenacThe risk or severity of adverse effects can be increased when Tasosartan is combined with Diclofenac.
DiflunisalThe risk or severity of adverse effects can be increased when Tasosartan is combined with Diflunisal.
DihydroergotamineThe metabolism of Tasosartan can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Tasosartan can be decreased when combined with Diltiazem.
DoxycyclineThe metabolism of Tasosartan can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Tasosartan can be decreased when combined with Dronedarone.
DrospirenoneTasosartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Tasosartan is combined with Droxicam.
EfavirenzThe serum concentration of Tasosartan can be decreased when it is combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Enalapril.
EnalaprilatThe risk or severity of adverse effects can be increased when Tasosartan is combined with Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Tasosartan.
EnzalutamideThe serum concentration of Tasosartan can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Tasosartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Tasosartan.
ErythromycinThe metabolism of Tasosartan can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Tasosartan can be decreased when it is combined with Eslicarbazepine acetate.
EtanerceptThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etoricoxib.
EtravirineThe serum concentration of Tasosartan can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Tasosartan is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Floctafenine.
FluconazoleThe metabolism of Tasosartan can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Tasosartan is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Flurbiprofen.
FluvoxamineThe metabolism of Tasosartan can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Tasosartan can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Tasosartan can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril.
FosphenytoinThe metabolism of Tasosartan can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Tasosartan can be increased when it is combined with Fusidic Acid.
HeparinHeparin may increase the hyperkalemic activities of Tasosartan.
HMPL-004The risk or severity of adverse effects can be increased when Tasosartan is combined with HMPL-004.
IbuprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Tasosartan is combined with Icatibant.
IdelalisibThe serum concentration of Tasosartan can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Tasosartan can be decreased when combined with Imatinib.
IndinavirThe metabolism of Tasosartan can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Tasosartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Indoprofen.
IsavuconazoniumThe metabolism of Tasosartan can be decreased when combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Tasosartan is combined with Isoxicam.
IsradipineThe metabolism of Tasosartan can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Tasosartan can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Tasosartan can be increased when it is combined with Ivacaftor.
KebuzoneThe risk or severity of adverse effects can be increased when Tasosartan is combined with Kebuzone.
KetoconazoleThe metabolism of Tasosartan can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ketorolac.
LeflunomideThe risk or severity of adverse effects can be increased when Tasosartan is combined with Leflunomide.
LisinoprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Tasosartan.
LopinavirThe metabolism of Tasosartan can be decreased when combined with Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lornoxicam.
LovastatinThe metabolism of Tasosartan can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Loxoprofen.
LuliconazoleThe serum concentration of Tasosartan can be increased when it is combined with Luliconazole.
LumiracoxibThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tasosartan is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Tasosartan is combined with Masoprocol.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Tasosartan is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Tasosartan is combined with Metamizole.
MifepristoneThe metabolism of Tasosartan can be decreased when combined with Mifepristone.
MitotaneThe serum concentration of Tasosartan can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Tasosartan can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Moexipril.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nabumetone.
NadroparinNadroparin may increase the hyperkalemic activities of Tasosartan.
NafcillinThe serum concentration of Tasosartan can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Tasosartan is combined with NCX 4016.
NefazodoneThe metabolism of Tasosartan can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Tasosartan can be decreased when combined with Nelfinavir.
NepafenacThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nepafenac.
NetupitantThe serum concentration of Tasosartan can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Tasosartan can be decreased when combined with Nevirapine.
NicorandilNicorandil may increase the hyperkalemic activities of Tasosartan.
Niflumic AcidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Niflumic Acid.
NilotinibThe metabolism of Tasosartan can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nimesulide.
OlaparibThe metabolism of Tasosartan can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olsalazine.
OmapatrilatThe risk or severity of adverse effects can be increased when Tasosartan is combined with Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Tasosartan is combined with Orgotein.
OsimertinibThe serum concentration of Tasosartan can be increased when it is combined with Osimertinib.
OxaprozinThe risk or severity of adverse effects can be increased when Tasosartan is combined with Oxaprozin.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tasosartan is combined with Oxyphenbutazone.
PalbociclibThe serum concentration of Tasosartan can be increased when it is combined with Palbociclib.
ParecoxibThe risk or severity of adverse effects can be increased when Tasosartan is combined with Parecoxib.
ParnaparinParnaparin may increase the hyperkalemic activities of Tasosartan.
PentobarbitalThe metabolism of Tasosartan can be increased when combined with Pentobarbital.
PerindoprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Perindopril.
PhenobarbitalThe metabolism of Tasosartan can be increased when combined with Phenobarbital.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Tasosartan is combined with Phenylbutazone.
PhenytoinThe metabolism of Tasosartan can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pimecrolimus.
PirfenidoneThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Tasosartan is combined with Piroxicam.
PosaconazoleThe metabolism of Tasosartan can be decreased when combined with Posaconazole.
PrimidoneThe metabolism of Tasosartan can be increased when combined with Primidone.
PropacetamolThe risk or severity of adverse effects can be increased when Tasosartan is combined with Propacetamol.
PTC299The risk or severity of adverse effects can be increased when Tasosartan is combined with PTC299.
QuinaprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Quinapril.
RamiprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ramipril.
RanolazineThe metabolism of Tasosartan can be decreased when combined with Ranolazine.
RescinnamineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Rescinnamine.
ResveratrolThe risk or severity of adverse effects can be increased when Tasosartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Tasosartan.
RifabutinThe metabolism of Tasosartan can be increased when combined with Rifabutin.
RifampicinThe metabolism of Tasosartan can be increased when combined with Rifampicin.
RifapentineThe metabolism of Tasosartan can be increased when combined with Rifapentine.
RitonavirThe metabolism of Tasosartan can be decreased when combined with Ritonavir.
RofecoxibThe risk or severity of adverse effects can be increased when Tasosartan is combined with Rofecoxib.
SalicylamideThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salsalate.
SaquinavirThe metabolism of Tasosartan can be decreased when combined with Saquinavir.
SeratrodastThe risk or severity of adverse effects can be increased when Tasosartan is combined with Seratrodast.
SildenafilThe metabolism of Tasosartan can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Tasosartan can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Tasosartan can be increased when it is combined with Simeprevir.
SpiraprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Spirapril.
SpironolactoneTasosartan may increase the hyperkalemic activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Tasosartan is combined with SRT501.
St. John's WortThe serum concentration of Tasosartan can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Tasosartan can be increased when it is combined with Stiripentol.
SulfasalazineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Sulfasalazine.
SulfisoxazoleThe metabolism of Tasosartan can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Tasosartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Suprofen.
TelaprevirThe metabolism of Tasosartan can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Tasosartan can be decreased when combined with Telithromycin.
TemocaprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Tasosartan is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tiaprofenic acid.
TiclopidineThe metabolism of Tasosartan can be decreased when combined with Ticlopidine.
TinzaparinTinzaparin may increase the hyperkalemic activities of Tasosartan.
TocilizumabThe serum concentration of Tasosartan can be decreased when it is combined with Tocilizumab.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tolmetin.
TolvaptanTolvaptan may increase the hyperkalemic activities of Tasosartan.
TrandolaprilThe risk or severity of adverse effects can be increased when Tasosartan is combined with Trandolapril.
TranilastThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tranilast.
TriamtereneTasosartan may increase the hyperkalemic activities of Triamterene.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Tasosartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Tasosartan is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Tasosartan is combined with Valdecoxib.
VenlafaxineThe metabolism of Tasosartan can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Tasosartan can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Tasosartan can be decreased when combined with Voriconazole.
ZaltoprofenThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zileuton.
ZiprasidoneThe metabolism of Tasosartan can be decreased when combined with Ziprasidone.
ZomepiracThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Elokdah HM, Friedrichs GS, Chai SY, Harrison BL, Primeau J, Chlenov M, Crandall DL: Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71. [PubMed:12113820 ]
  2. Unger T: Pharmacology of AT1-receptor blockers. Blood Press Suppl. 2001;(3):5-10. [PubMed:11683476 ]
  3. Maillard MP, Rossat J, Brunner HR, Burnier M: Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. [PubMed:11046101 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor antagonist activity
Specific Function:
Receptor for angiotensin II. Cooperates with MTUS1 to inhibit ERK2 activation and cell proliferation.
Gene Name:
AGTR2
Uniprot ID:
P50052
Molecular Weight:
41183.45 Da
References
  1. Unger T: Pharmacology of AT1-receptor blockers. Blood Press Suppl. 2001;(3):5-10. [PubMed:11683476 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:15 / Updated on August 17, 2016 12:23